Aurora Cannabis Falls On Weak 2026 Outlook Despite Record Q4 Revenues

Aurora Cannabis reported record Q4 2025 revenues driven by international medical cannabis sales; however, the company's weak 2026 outlook and low gross profit led to a significant stock price decline, with shares down 31% over the past week. Despite achieving free cash flow for the quarter, overall sector weakness contributes to a Hold rating on the stock.

Analysis

Aurora Cannabis (ACB) presents a conflicting financial profile where record Q4-2025 revenues are being overshadowed by significant forward-looking concerns. The top-line growth, driven by an expansion in international medical cannabis sales, is a positive operational signal. However, this has been completely negated in the market's view by a weak outlook for fiscal 2026 and low gross profit margins, which signal underlying profitability challenges. The market's reaction has been severe, with the stock falling 31% in the past week and 26% over the last year. While the company did achieve positive free cash flow during the quarter, it was insufficient to allay investor fears about the weak guidance. These company-specific issues are further compounded by a backdrop of general sector weakness, creating substantial headwinds for the stock's performance.

Key Decisions for Investors

• Investors should look past the headline record revenue and focus on the more critical forward-looking indicators, particularly the weak 2026 guidance and persistent low gross profitability.
• Given the stock's precipitous 31% drop in the past week, a cautious stance is warranted as the market is clearly pricing in significant future headwinds and a lack of confidence in the company's path to sustainable profit.
• It is prudent to monitor not only for improvements in gross margin in future earnings reports but also for a shift in the broader cannabis sector sentiment, as the cited weakness may suppress the stock regardless of company-specific execution.